» » »

Gene Therapy and Emphysema Boston MA

A single treatment with a new method of gene therapy may offer lifetime protection against the progression of the lung disease emphysema, according to the results of a study in mice. The most common form of emphysema in young people is Alpha-1 Anti-trypsin Deficiency, caused by a mutation in the alpha-1 anti-trypsin gene, the authors of the study pointed out.

Maya Berdzenishvili, MD
1 Emerson Pl Apt 5Q
Boston, MA
Specialties
Internal Medicine, Pulmonary Critical Care Medicine
Gender
Female
Education
Medical School: Tbilisi State Med Inst, Tbilisi, Georgia
Graduation Year: 1986

Data Provided by:
Kari E Roberts
(617) 636-6377
750 Washington Street, #257
Boston, MA
Specialty
Internal Medicine, Pulmonary Disease

Data Provided by:
John Norman Unterborn, MD
(617) 636-7753
750 Washington St
Boston, MA
Specialties
Internal Medicine, Pulmonary Critical Care Medicine
Gender
Male
Education
Medical School: Univ Of Md Sch Of Med, Baltimore Md 21201
Graduation Year: 1989

Data Provided by:
Marya Davida Zilberberg, MD
(978) 927-4110
750 Washington St # 369
Boston, MA
Specialties
Internal Medicine, Pulmonary Critical Care Medicine
Gender
Female
Education
Medical School: Boston Univ Sch Of Med, Boston Ma 02118
Graduation Year: 1992

Data Provided by:
Paul Frederick Currier, MD
(617) 724-7823
55 Fruit St
Boston, MA
Specialties
Internal Medicine, Pulmonary Critical Care Medicine
Gender
Male
Education
Medical School: Vanderbilt Univ Sch Of Med, Nashville Tn 37232
Graduation Year: 1996

Data Provided by:
John Bernardo
(617) 638-7480
720 Harrison Ave
Boston, MA
Specialty
Pulmonary Disease

Data Provided by:
David M Center
(617) 638-7480
720 Harrison Ave
Boston, MA
Specialty
Pulmonary Disease

Data Provided by:
George Franklin Barker
(617) 726-1721
55 Fruit St
Boston, MA
Specialty
Internal Medicine, Pulmonary Disease, Critical Care (Intensivists)

Data Provided by:
David C Rishikof
(617) 638-7480
850 Harrison Ave
Boston, MA
Specialty
Pulmonary Disease

Data Provided by:
Robert E Hillberg
(617) 573-2611
125 Nashua St
Boston, MA
Specialty
Pulmonary Disease

Data Provided by:
Data Provided by:

Gene Therapy and Emphysema

Provided By:

TUESDAY, Dec. 22 (HealthDay News) -- A single treatment with a new method of gene therapy may offer lifetime protection against the progression of the lung disease emphysema, according to the results of a study in mice.

The most common form of emphysema in young people is Alpha-1 Anti-trypsin Deficiency, caused by a mutation in the alpha-1 anti-trypsin gene, the authors of the study pointed out.

In experiments on mice, researchers at the Boston University School of Medicine developed a system that can deliver genes selectively to as many as 70 percent of the lung's alveolar macrophages, which play an important role in emphysema.

Using this new approach, the researchers achieved sustained expression of normal human alpha-1 anti-trypsin (hAAT) protein at levels that improved emphysema in mice.

"The lung macrophages carrying the therapeutic gene survived in the lungs' air sacs for the two-year lifetime of the treated mice following a single intra-tracheal injection of the lentiviral vector we had engineered," study senior author Dr. Darrell Kotton, an associate professor of medicine and pathology and co-director of the Center for Regenerative Medicine at Boston University School of Medicine, said in a news release.

"Our results challenge the dogma that lung macrophages are short-lived and suggest these differentiated cells as a target cell that may be considered for in vivo gene therapy applications, including the sustained correction of hAAT deficiency," lead author Dr. Andrew Wilson, an assistant professor of medicine, said in the news release.

The study was published online Dec. 21 in the Journal of Clinical Investigation.

More information

The American Lung Association has more about emphysema.

SOURCE: Boston University Medical Center, news release, Dec. 21, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com